Skip to main content
. 2014 Sep 15;7(10):6725–6733.

Table 1.

Patient characteristics in each study

Author (yrs.) N Age (mean yrs.) HG (Grade, N) Treatment TP53 Method IHC antibody IHC cutoff PCR Exons Death in 2 yrs. n (%)
Papai (1997) [10] 21 20 17 (Grade IIb) NC + surgery expression IHC DO-7 5% 8 (38)
4 (Grade IIa)
Goto (1998) [11] 32 16 23 (Grade III) NC + surgery expression IHC/PCR DO-7/Rsp53 > 0% MS 14 (44)
9 (Grade IV)
Jensen (1998) [12] 25 67 9 (Grade III) surgery expression IHC DO-7 10% 11 (44)
16 (Grade IV)
Yokoyama (1998) [13] 17 15 8 (Grade III) NC + surgery mutation PCR* 4-8 1 (6)
7 (Grade IV)
Gorlick (1999) [14] 53 17 11 (Grade I) NC + surgery expression IHC 1801/DO-7 > 0% 16 (30)
24 (Grade II)
10 (Grade III)
8 (Grade IV)
Tsuchiya (2000) [16] 27 15 NA NC + surgery mutation PCR* 5-9 11 (41)
Uozaki (2000) [17] 70 16 43 (Grade III) NC + surgery expression IHC DO-7 10% 17 (24)
27 (Grade IV)
Oda (2000) [15] 25 17 6 (Grade III) NC + surgery expression IHC NR 10% 4 (16)
19 (Grade IV)
Kawaguchi (2002) [18] 23 55 8 (Grade III) surgery mutation IHC/PCR 1801 10% 5-9 12 (52)
15 (Grade IV)
Tsai (2004) [21] 22 16 3 (Grade II) NC + surgery expression IHC DO-7 5% 9 (41)
11 (Grade IIa)
8 (Grade III)
Ferrari (2004) [20] 19 15 NA surgery expression IHC DO-7 25% 3 (16)
Kaseta (2008) [22] 35 30 4 (Low grade) NC + surgery expression IHC DO-7 25% NA
31 (High grade)
Ozger (2009) [23] 45 20 NA NC + surgery expression IHC DO-7 10% 6 (13)
Boulytcheva (2010) [24] 40 NA 4 (Grade I) surgery expression IHC DO-7 10% NA
22 (Grade II)
2 (Grade III)
12 (Grade IV)
Hu (2010) [25] 44 25 5 (Grade I) NC + surgery expression IHC NR 10% NA
16 (Grade II)
16 (Grade III)
7 (Grade IV)
Seidinger (2011) [26] 41 NA NA surgery mutation IHC/PCR DO-7 NR 10 12 (29)
Wu (2012) [27] 56 Range (13-37) 56 (Grade IIb) NC + surgery expression IHC DO-7 10% NA

Note: HG, histological grades; N, number; NC, neoadjuvant chemotherapy;

*

PCR/single-strand conformational polymorphism.